Does Rallies show Form 4 insider transactions for ABEO?

Yes. Rallies tracks ABEO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ABEO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ABEO. It does not provide personalized investment advice.

ABEO (Abeona Therapeutics Inc. Common Stock) Stock Analysis - Insider Trades

Abeona Therapeutics Inc. Common Stock (ABEO) is a publicly traded Healthcare sector company. As of May 21, 2026, ABEO trades at $5.36 with a market cap of $306.06M and a P/E ratio of -3.42. ABEO moved +4.10% today. Year to date, ABEO is +1.92%; over the trailing twelve months it is -17.13%. Its 52-week range spans $3.93 to $7.54. Analyst consensus is strong buy with an average price target of $20.67. Rallies surfaces ABEO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ABEO stock inside the company?

Recent ABEO insider activity includes Crombez Eric sold 26.14K, Vasanthavada Madhav sold 5.55K, Seshadri Vishwas sold 29.98K, Vazzano Joseph Walter sold 785, and Silverstein Christine Berni sold 20.07K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ABEO Key Metrics

Key financial metrics for ABEO
Metric	Value
Price	$5.36
Market Cap	$306.06M
P/E Ratio	-3.42
EPS	$-1.55
Dividend Yield	0.00%
52-Week High	$7.54
52-Week Low	$3.93
Volume	5
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-63.73M
Gross Margin	0.00%

Recent ABEO Insider Trades

Crombez Eric sold 26.14K (~$144.64K) on May 15, 2026.
Vasanthavada Madhav sold 5.55K (~$33.07K) on May 11, 2026.
Seshadri Vishwas sold 29.98K (~$131.48K) on Mar 31, 2026.
Vazzano Joseph Walter sold 785 (~$3.74K) on Mar 16, 2026.
Silverstein Christine Berni sold 20.07K (~$102.17K) on Feb 2, 2026.

Latest ABEO News

Abeona Therapeutics Reports Strong Q1 2026 Revenue Growth and Pipeline Update — May 14, 2026
Abeona’s Q1 ZEVASKYN Revenue Rises to $8.7M; Licenses $7M PSMA Therapy — May 13, 2026
Children’s Hospital of Philadelphia Joins as Sixth ZEVASKYN Treatment Center — May 11, 2026
Abeona Names Keith Goldan to Board, Veteran CFO with Two Syndax Approvals — Apr 7, 2026
Abeona Activates NewYork-Presbyterian/Columbia as Fifth ZEVASKYN Treatment Center — Apr 2, 2026

ABEO Analyst Consensus

6 analysts cover ABEO: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $20.67.

Common questions about ABEO

Who is trading ABEO stock inside the company?: Recent ABEO insider activity includes Crombez Eric sold 26.14K, Vasanthavada Madhav sold 5.55K, Seshadri Vishwas sold 29.98K, Vazzano Joseph Walter sold 785, and Silverstein Christine Berni sold 20.07K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ABEO?: Yes. Rallies tracks ABEO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ABEO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ABEO. It does not provide personalized investment advice.